Literature DB >> 18680736

Genetic factors contribute to patient-specific warfarin dose for Han Chinese.

Ting-Liang Wang1, Hong-Lei Li, Wen-Ye Tjong, Qian-Su Chen, Guan-Sheng Wu, Hai-Tao Zhu, Zi-Shan Hou, Shu Xu, Sheng-Jun Ma, Madeline Wu, Susan Tai.   

Abstract

BACKGROUND: Warfarin is a commonly prescribed anticoagulant drug for the prevention of thromboses. To address the association of genetic factors and warfarin dosage for ethnic Han Chinese, we genotyped six candidate genes involved in the warfarin interactive pathway with focus on SNPs with reported association with warfarin dose.
METHODS: We recruited a study population consisted of 318 patients receiving warfarin treatment and 995 healthy controls. PCR and direct sequencing were used to identify the sequence polymorphisms.
RESULTS: In our study population, SNP rs1799853 of CYP2C9, rs1687390 of ORM1-2, and rs2069919 of PROC showed no variation. SNPs rs12714145 of GGCX and rs1799809 of PROC showed no significant correlation with warfarin dose. The associations of SNPs rs9934438 and rs9923231 of VKORC1, the 3 (rs1057910) and C(-65) (rs9332127) alleles of CYP2C9, and SNP rs4653436 of EPHXI with the dose of warfarin were significant.
CONCLUSION: A multiple regression model based on the genetic polymorphisms of VKORC1, CYP2C9, EPHX1 and the non-genetic factors of age and body weight can explain 40.2% of the variance in warfarin dose in Han Chinese patients. Translation of this knowledge into clinical guidelines for warfarin prescription may improve the safety and efficacy of warfarin treatment among Han Chinese.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18680736     DOI: 10.1016/j.cca.2008.07.005

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  22 in total

1.  New genetic variant that might improve warfarin dose prediction in African Americans.

Authors:  Hedi Schelleman; Colleen M Brensinger; Jinbo Chen; Brian S Finkelman; Mark J Rieder; Stephen E Kimmel
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

2.  CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Authors:  Han-Jing Cen; Wu-Tao Zeng; Xiu-Yu Leng; Min Huang; Xiao Chen; Jia-Li Li; Zhi-Ying Huang; Hui-Chang Bi; Xue-Ding Wang; Yan-Ling He; Fan He; Rui-Na Zhou; Qi-Shan Zheng; Li-Zi Zhao
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

3.  A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Authors:  Su-Jun Lee; Yin Jin Jang; Eun-Young Cha; Ho-Sook Kim; Sang Seop Lee; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

4.  The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement.

Authors:  Shi-Long Zhong; Yuan Liu; Xi-Yong Yu; Dan Xu; Hong-Hong Tan; Qiu-Xiong Lin; Min Yang; Hai-Yan Lao; Shu-Guang Lin
Journal:  Eur J Clin Pharmacol       Date:  2011-02-12       Impact factor: 2.953

5.  Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Authors:  Dhakchinamoorthi Krishna Kumar; Deepak Gopal Shewade; Marie-Anne Loriot; Philippe Beaune; Jayaraman Balachander; B V Sai Chandran; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2013-09-10       Impact factor: 2.953

6.  VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.

Authors:  Qiang Gu; Yan Kong; Jörn Schneede; Ying-Bin Xiao; Lin Chen; Qian-Jin Zhong; Xue-Feng Wang; Jia Hao; Bai-Cheng Chen; Jing-Jin Chen
Journal:  Eur J Clin Pharmacol       Date:  2010-09-15       Impact factor: 2.953

7.  Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

Authors:  Ruijuan Liang; Lei Li; Cuilan Li; Yuanfeng Gao; Wenling Liu; Dayi Hu; Yihong Sun
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 8.  The pharmacogenetics of the response to warfarin in Chinese.

Authors:  May P S Lam; Bernard M Y Cheung
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 9.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

10.  Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.

Authors:  Lian Sheng Wang; Jing Jing Shang; Shu Ya Shi; Yan Qing Zhang; Jian Lin; Zhi Hua Guo; Yi Chen Wang; Jie Tang; Jie Liu; Ying Zi Liu; Zhi Li; Zhi Rong Tan; Hong Hao Zhou; Hai He Jiang; Hai Tang Xie
Journal:  Eur J Clin Pharmacol       Date:  2012-12-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.